1149 related articles for article (PubMed ID: 17919270)
41. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
Brenner DM; Chey WD
Rev Gastroenterol Disord; 2009; 9(1):7-15. PubMed ID: 19367213
[TBL] [Abstract][Full Text] [Related]
42. Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study.
Hatakka K; Blomgren K; Pohjavuori S; Kaijalainen T; Poussa T; Leinonen M; Korpela R; Pitkäranta A
Clin Nutr; 2007 Jun; 26(3):314-21. PubMed ID: 17353072
[TBL] [Abstract][Full Text] [Related]
43. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
Choi CH; Jo SY; Park HJ; Chang SK; Byeon JS; Myung SJ
J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
[TBL] [Abstract][Full Text] [Related]
44. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial.
de Vrese M; Winkler P; Rautenberg P; Harder T; Noah C; Laue C; Ott S; Hampe J; Schreiber S; Heller K; Schrezenmeir J
Clin Nutr; 2005 Aug; 24(4):481-91. PubMed ID: 16054520
[TBL] [Abstract][Full Text] [Related]
45. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study.
Guandalini S; Magazzù G; Chiaro A; La Balestra V; Di Nardo G; Gopalan S; Sibal A; Romano C; Canani RB; Lionetti P; Setty M
J Pediatr Gastroenterol Nutr; 2010 Jul; 51(1):24-30. PubMed ID: 20453678
[TBL] [Abstract][Full Text] [Related]
46. Protection mechanism of probiotic combination against human pathogens: in vitro adhesion to human intestinal mucus.
Collado MC; Jalonen L; Meriluoto J; Salminen S
Asia Pac J Clin Nutr; 2006; 15(4):570-5. PubMed ID: 17077078
[TBL] [Abstract][Full Text] [Related]
47. Treating irritable bowel syndrome with probiotics: the evidence.
Parkes GC; Sanderson JD; Whelan K
Proc Nutr Soc; 2010 May; 69(2):187-94. PubMed ID: 20236566
[TBL] [Abstract][Full Text] [Related]
48. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial.
Sadrin S; Sennoune SR; Gout B; Marque S; Moreau J; Grillasca J; Pons O; Maixent JM
Cell Mol Biol (Noisy-le-grand); 2017 Sep; 63(9):122-131. PubMed ID: 28980935
[TBL] [Abstract][Full Text] [Related]
49. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
50. The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics.
Koning CJ; Jonkers D; Smidt H; Rombouts F; Pennings HJ; Wouters E; Stobberingh E; Stockbrügger R
Br J Nutr; 2010 May; 103(10):1452-60. PubMed ID: 20021703
[TBL] [Abstract][Full Text] [Related]
51. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial.
Bittner AC; Croffut RM; Stranahan MC; Yokelson TN
Clin Ther; 2007 Jun; 29(6):1153-60. PubMed ID: 17692729
[TBL] [Abstract][Full Text] [Related]
52. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study.
Colecchia A; Vestito A; La Rocca A; Pasqui F; Nikiforaki A; Festi D;
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):349-58. PubMed ID: 17108864
[TBL] [Abstract][Full Text] [Related]
53. Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients.
Mearin F; Badía X; Balboa A; Benavent J; Caballero AM; Domínguez-Muñoz E; Garrigues V; Piqué JM; Roset M; Cucala M; Figueras M;
Aliment Pharmacol Ther; 2006 Mar; 23(6):815-26. PubMed ID: 16556184
[TBL] [Abstract][Full Text] [Related]
54. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome.
Dumitraşcu DL; Stănculete M
Rom J Intern Med; 2006; 44(3):273-80. PubMed ID: 18386606
[TBL] [Abstract][Full Text] [Related]
55. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada.
Ranganathan N; Friedman EA; Tam P; Rao V; Ranganathan P; Dheer R
Curr Med Res Opin; 2009 Aug; 25(8):1919-30. PubMed ID: 19558344
[TBL] [Abstract][Full Text] [Related]
56. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
57. Temporary sacral nerve stimulation for treatment of irritable bowel syndrome: a pilot study.
Lundby L; Krogh K; Buntzen S; Laurberg S
Dis Colon Rectum; 2008 Jul; 51(7):1074-8. PubMed ID: 18418655
[TBL] [Abstract][Full Text] [Related]
58. Effect of gluten-free diet and co-morbidity of irritable bowel syndrome-type symptoms on health-related quality of life in adult coeliac patients.
Usai P; Manca R; Cuomo R; Lai MA; Boi MF
Dig Liver Dis; 2007 Sep; 39(9):824-8. PubMed ID: 17644056
[TBL] [Abstract][Full Text] [Related]
59. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
Urgesi R; Casale C; Pistelli R; Rapaccini GL; de Vitis I
Eur Rev Med Pharmacol Sci; 2014; 18(9):1344-53. PubMed ID: 24867512
[TBL] [Abstract][Full Text] [Related]
60. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome.
Williams RE; Black CL; Kim HY; Andrews EB; Mangel AW; Buda JJ; Cook SF
Aliment Pharmacol Ther; 2006 Jun; 23(11):1667-75. PubMed ID: 16696818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
